The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA's Overreach on Compounded Peptides